1. Search Result
Search Result
Results for "

BRD2/3/4

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15743
    Birabresib
    Maximum Cited Publications
    39 Publications Verification

    OTX-015; MK-8628

    Epigenetic Reader Domain Cancer
    Birabresib (OTX-015) is a potent bromodomain (BRD2/3/4) inhibitor with IC50s ranging from 92 to 112 nM.
    Birabresib
  • HY-114416

    Epigenetic Reader Domain Cancer
    GS-626510 is a potent, and orally active BET family bromodomains inhibitor, with Kd values of 0.59-3.2 nM for BRD2/3/4, with IC50 values of 83 nM and 78 nM foe BD1 and BD2, respectively .
    GS-626510
  • HY-15743A
    (R)-Birabresib
    1 Publications Verification

    (R)-OTX-015; (R)-MK-8628

    Drug Isomer Cancer
    (R)-Birabresib is the isomer of Birabresib (HY-15743), and can be used as an experimental control. Birabresib (OTX-015) is a potent bromodomain (BRD2/3/4) inhibitor with IC50s ranging from 92 to 112 nM.
    (R)-Birabresib
  • HY-13031

    Epigenetic Reader Domain Apolipoprotein Cancer
    GW 841819X is a potent inducer of the ApoA1 report gene, with an EC170 of 0.22 µM, and its pIC50 for Brd2/3/4 is 5.9/6.2/6.3 .
    GW 841819X
  • HY-15743R

    OTX-015 (Standard); MK-8628 (Standard)

    Reference Standards Epigenetic Reader Domain Cancer
    Birabresib (Standard) is the analytical standard of Birabresib. This product is intended for research and analytical applications. Birabresib (OTX-015) is a potent bromodomain (BRD2/3/4) inhibitor with IC50s ranging from 92 to 112 nM.
    Birabresib (Standard)
  • HY-172562

    PROTACs Epigenetic Reader Domain Cancer
    BTR2004 is a selective BET family (BRD2/3/4) protein PROTAC degrader. BTR2004 forms a ternary complex with BRD proteins and KLHL20, inducing ubiquitination and proteasomal degradation through the UPS pathway. BTR2004 is promising for research of PC3 prostate cancer and MDA-MB-231 breast cancer cell lines. Pink: (+)-JQ1-OH (HY-161125); Blue: BTR2000 (HY-172563); Black: Linker (HY-W015236) .
    BTR2004
  • HY-180804

    Epigenetic Reader Domain Cancer
    CZL-077 is a potent, selective, and orally active p300/CBP bromodomain (BRD) inhibitor (p300 IC50 = 0.034 μM, CBP IC50 = 0.052 μM) exhibiting high selectivity over the BRDs of BET proteins (BRD2/3/4). CZL-077 inhibits cell growth with IC50 values of 0.024 μM and 5.6 μM in OPM-2 and 22RV1 cells, respectively. CZL-077 shows antitumor efficacy in OPM-2 and 22RV1 xenograft mouse models. CZL-077 can be used for multiple myeloma and prostate cancer research .
    CZL-077

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: